Contreras JMS

Idioma: Ingles.
Referencias bibliográficas: 11
Paginas: 56-57
Archivo PDF: 30.73 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Darby SC, et al. Mortality from liver cancer and liver disease in hemophilic men given blood products contaminated with HCV. Lancet 1997; 350: 1425-31.

2. Franchini M, et al. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood 2001; 98: 1836-41.

3. Goedert J, et al. End-stage liver disease in persons with hemophilia transfusion associated infections. Blood 2002; 100: 1584-89.

4. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

5. Worman. Hepatitis C: 2002.

6. Peter’s, et al. Medscape HIV/AIDS Journal. 2002; 8(1).

7. Santagostino E, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003; 102: 78-82.

8. Grazia Rumi M, et al. A multicenter controlled randomized open trial of Interferon alfa-2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997; 89: 3529-33.

9. Santagostino E, et al. Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. Blood 2002; 99: 1089-91.

10. Hadziyannis S, et al. Interferon alfa-2a and rivabirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and rivabirin dose. Ann Intern Med 2004; 140(5): 346-55.

11. Manns MP, et al. Peginterferon alfa-2b plus rivabirin compared with interferon alfa-2b plus rivabirin for the initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.